

# INTERNATIONAL CONSENSUS: TOPICAL OXYGEN THERAPY

## 2023 ADA EVIDENCE RATING A

Frykberg R, Andersen C, et al. Use of topical oxygen therapy in wound healing. *Journal of Wound Care*. 2023;32(S8B):S3–S30.

### Executive Summary

This consensus document represents the collective expertise of a panel of 9 key opinion leaders from the US and Europe. It serves as a critical update to the 2017 EWMA document, synthesizing evidence from over 45 peer-reviewed articles to establish best practices for Topical Oxygen Therapy (TOT) in hard-to-heal wounds.

**A** **ADA Grade A**  
Evidence Rating (2023)

**8.2 Million**  
Medicare Beneficiaries

**\$96.8 Billion**  
Projected Wound Costs


**✓ Purpose:** To define mechanisms, review clinical evidence, and provide actionable recommendations for incorporating TOT into standard of care.


### The Critical Role of Oxygen in Healing

Chronic wounds are inherently hypoxic. Oxygen is essential for cell metabolism, collagen synthesis, and antimicrobial defense. Without sufficient pO<sub>2</sub>, the healing cascade stalls.

**100**  
mmHg (Healthy) → **~10**  
mmHg (Wound)

#### Impact of Hypoxia on Enzymes

 Enzymatic activity falls to **10–30%** of max efficiency at low oxygen tension.

 TOT reverses local hypoxia, restoring the microenvironment and upregulating angiogenic factors (VEGF, FGF-2).



### Summary of TOT Modalities & Evidence

MODALITY	MECHANISM & DELIVERY	ADA EVIDENCE GRADE
<b>Continuous Delivery of Oxygen (CDO)</b>	Continuous low flow of pure oxygen (24/7). <i>Wearable, silent, ambulatory device.</i>	<b>A</b>
<b>Higher Cyclical Pressure Oxygen (HCPO)</b>	Humidified oxygen under cyclical pressure (10-50 mbar). <i>90 mins/day, 5 days/week (Extremity chamber).</i>	<b>A</b>
<b>Haemoglobin Spray</b>	Facilitates oxygen diffusion into wound bed. <i>Liquid spray applied at dressing changes.</i>	<b>B</b>
<b>Other Modalities</b>	Disposable CDO, Low Constant Pressure Oxygen (LCPO), Oxygen Dressings.	<b>C</b>



# Clinical Evidence Highlights

Key Findings from Randomized Controlled Trials & Systematic Reviews



## CDO in Diabetic Foot Ulcers

-  **Significantly Higher Healing Rates**  
46% vs 22% complete healing at 12 weeks compared to placebo (p=0.016).
-  **Accelerated Closure**  
Time to 50% healing was nearly halved in the CDO group. Relative performance increased with larger, more chronic wounds.



## HCPO in Diabetic Foot Ulcers

-  **Reduced Hospitalizations**  
Real-world data showed an 82% reduction in hospitalizations (p<0.0001) and 73% fewer amputations.
-  **Long-term Durability**  
12-month closure rate: 56% vs 27% for standard of care (p=0.013).

## HCPO in Venous Leg Ulcers

-  **Superior Closure Rates**  
76% vs 46% complete healing at 12 weeks (p<0.0001) in refractory non-healing VLUs.
-  **Faster Healing Time**  
Median time to full closure: 57 days (HCPO) vs 107 days (Conventional Compression).

## Cost-Effectiveness

-  **Economic Impact**  
CDO vs NPWT: Saves ~\$4,800 per patient.  
CDO vs HBOT: Saves up to \$14,060 per patient.
-  **Simulation Results**  
79% of economic simulations demonstrated that CDO was a cost-effective intervention for chronic wounds.

## Clinical Recommendations for Implementation

- > **Primary Trigger:** Consider TOT when wounds fail to reduce in size by ≥50% after 4 weeks of standard of care.
- > **Early Intervention:** Earlier use is better; consider for early treatment of ischaemic DFUs.
- > **Broad Applicability:** Appropriate for most non-neoplastic hard-to-heal wounds (DFU, VLU, Pressure Injuries).
- > **Administration:** Self-administration is possible after brief training; multidisciplinary approach recommended.

## Key Takeaway & Guideline Updates

TOT is safe, clinically effective, and cost-efficient. The substantial body of high-quality evidence has led to major guideline updates in 2023.

**ADA Standards of Care (2023)** Gave TOT its highest-ever evidence rating (**Grade A**) for chronic diabetic foot ulcers.

**IWGDF Recommendation (2023)** Made its first-ever recommendation to consider adjunctive TOT for hard-to-heal DFUs.

